Die folgenden Informationen liegen ausschließlich in englischer Sprache vor. 

Tübingen, Germany, 7 July 2026 – Prime Vector Technologies GmbH (PVT), a clinical-stage biotechnology company focusing on the development of viral vector-based vaccines, today announced that it has entered into an agreement with Boehringer Ingelheim for the assignment of certain patents and the exclusive licensing of its Orf virus (ORFV) platform for the development of next-generation cancer vaccines. PVT’s ORFV platform is designed as a versatile viral vector platform for potential application in the
preventive and therapeutic vaccine areas.

Under the terms of the agreement, PVT is eligible to receive an upfront payment, development, regulatory and commercial milestone payments, as well as royalties on future product sales.

Ralf Amann, CEO of PVT, said, “We are pleased to partner with Boehringer on the development of new cancer immunotherapy approaches based on our ORFV platform. Having successfully advanced the platform from preclinical research through GMP manufacturing and Phase I/IIa clinical evaluation in infectious diseases, we are excited to further explore its potential in oncology with a partner that brings deep
scientific and development expertise.”

“We are committed to developing differentiated new treatment options with the potential to have an unprecedented impact for people living with cancer, and this agreement adds another promising approach to that effort” said Mark Petronczki, Head of Oncology Research at Boehringer Ingelheim. “We look forward to incorporating the ORFV platform into our work to build the next-generation of cancer vaccines and combination treatments for patients.”

Boehringer Ingelheim intends to evaluate the platform both as a standalone cancer vaccine approach and in combination with assets across its oncology pipeline.

The agreement supports PVT´s strategy of advancing the ORFV platform through partnerships that can fully explore its scientific and therapeutic potential for oncology applications that require payload flexibility, scalable design, and the ability to support broad patient applicability through off-the-shelf development approaches. Beyond this oncology partnership, PVT continues to pursue the broader potential of the ORFV platform in infectious diseases and other vaccine applications.